Abstract 226P
Background
Urothelial carcinoma (UC) has a highly complex genomic landscape. With the spread of immunotherapy, accurate stratification strategies are needed. As cancer tissues are now frequently screened for specific sets of mutations, a large number of samples has become available for analysis. Classification of patients with similar mutation profiles may help identifying subgroups of patients outcomes. However, classification based on somatic mutations is challenging due to the sparseness and heterogeneity of the data.
Methods
A retrospective study was performed to identify the prognosis-related somatic mutations from 192 UC in The Cancer Genome Atlas (TCGA) database. Cox regression were performed to screen out prognostic genes.
Results
A total of 176 genes were related with immuno-survival. Then, a stepwise multivariate Cox regression analysis was performed, and 14 gene were selected to establish a predictive model. Compared with the wildtype group, the patients with mutated signature had unfavorable to prognosis (p<0.001). ROC curve analysis demonstrated the predictive ability for 1-, 3-, 5-, and 10-year OS, with areas under the curve (AUCs) of 0.7684, 0.667,0.619 and 0.647, respectively. In mutated signature cohorts, the five most frequently mutated genes were TP53 (50%), KMT2D (43%), LRP1B (33%), PER1 (33%), and RNF213 (33%). Dissimilarly, the five most frequently mutated genes were TP53 58%), ARID1A (29%), KMT2D (29%), RNF213 (27%), and KDM6A (26%) in wildtype cohorts, which may imply that different characteristic states have different molecular mechanisms.
Conclusions
These data underline the potential value of using somatic mutations to accurately stratify UC patients into clinically actionable subgroups. This model could reduce overtreatment in UC patients with mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract